ReviewArteriosclerosis, thrombosis, and vascular biology2017
ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion.Clinical and experimental immunology · 2021Trial
- Proteomic and morphologic characterization of ovine macrophage differentiation and polarization.Scientific reports · 2025Article
- Influence of lifestyle risk factors and genetic predisposition on metabolic syndrome risk in Korean adults.Scientific reports · 2025Article
- Atherosclerosis: from lipid-lowering and anti-inflammatory therapies to targeting arterial retention of ApoB-containing lipoproteins.Frontiers in immunology · 2025Review
- PD-1 and CD73 on naive CD4Nature immunology · 2025Article
- Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.Frontiers in pharmacology · 2024Article
- Review
- Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review.Nutrients · 2023Review
- Myeloid CD40 deficiency reduces atherosclerosis by impairing macrophages' transition into a pro-inflammatory state.Cardiovascular research · 2023Article
- How the immune system shapes atherosclerosis: roles of innate and adaptive immunity.Nature reviews. Immunology · 2022Review
- Phenotypic Changes of Peripheral γδ T Cell and Its Subsets in Patients With Coronary Artery Disease.Frontiers in immunology · 2022Article
- Novel Diagnostic Biomarkers Related to Oxidative Stress and Macrophage Ferroptosis in Atherosclerosis.Oxidative medicine and cellular longevity · 2022Article
- Pig and Mouse Models of Hyperlipidemia and Atherosclerosis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Recent Advances on the Role and Therapeutic Potential of Regulatory T Cells in Atherosclerosis.Journal of clinical medicine · 2021Review
- Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease.Nature communications · 2021Article
- ApoB-Specific CD4Cells · 2021Review
- Article
- T cell subsets and functions in atherosclerosis.Nature reviews. Cardiology · 2020Review
- Cytotoxic T Lymphocyte-Associated Antigen-4 Protects Against Angiotensin II-Induced Kidney Injury in Mice.Circulation reports · 2020Article
- Adaptive immunity: an emerging player in the progression of NAFLD.Nature reviews. Gastroenterology & hepatology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectiveImmune cells play a critical role in atherosclerosis. Costimulatory and coinhibitory molecules of the tumor necrosis factor receptor and CD28 immunoglobulin superfamilies not only shape T-cell and B-cell responses but also have a major effect on antigen-presenting cells and nonimmune cells. APPROACH AND
resultsPharmacological inhibition or activation of costimulatory and coinhibitory molecules and genetic deletion demonstrated their involvement in atherosclerosis. This review highlights recent advances in understanding how costimulatory and coinhibitory pathways shape the immune response in atherosclerosis.
conclusionsInsights gained from costimulatory and coinhibitory molecule function in atherosclerosis may inform future therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.